Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518385 | 0.92 | DNM2 (0.44) | DNM2NUDT1 | |
| SCHEMBL8599872 | 0.88 | NUDT1 (0.36) | DNM2NUDT1 | |
| SCHEMBL6768499 | 0.84 | DNM2 (0.38) | DNM2ESR1ESR2 | |
| SCHEMBL6398903 | 0.79 | TLR8 (0.38) | DNM2 | |
| SCHEMBL8602832 | 0.79 | MAPT (0.38) | MAPTAPP | |
| SCHEMBL7642550 | 0.77 | CYP1A2 (0.33) | MAPTAPP | |
| SCHEMBL8599974 | 0.77 | DNM2 (0.37) | DNM2NUDT1MAPTESR1ESR2 | |
| SCHEMBL8598479 | 0.76 | NUDT1 (0.36) | NUDT1 | |
| SCHEMBL7636300 | 0.75 | NPC1 (0.35) | MAPT | |
| SCHEMBL7632057 | 0.74 | ADORA3 (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0736300-B1 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | OREAL (FR) | 2003-03-05 | — | — | EP | claimed |
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | PRUCHE FRANCIS (FR) | 2002-08-01 | — | — | US | claimed |
| EP-0829260-B1 | Use of at least one pyrimidine derivative substituted in position 6 as stimulant of tyrosinase | OREAL (FR) | 2002-05-15 | — | — | EP | claimed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | claimed |
| US-5772990-A | Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated | L'OREAL (FR) | 1998-06-30 | — | — | US | claimed |
| US-5756092-A | DRUGS OR COSMETIC MIXTURE TREATING SKIN DISORDERS, ALOPECIA | SOCIETEL'OREAL S.A. (FR) | 1998-05-26 | — | — | US | claimed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | claimed |
| EP-0519819-B1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | OREAL (FR) | 1995-07-19 | — | — | EP | claimed |
| JP-5186315-A | — | — | None | — | — | JP | disclosed |
| EP-1097980-B1 | Bathophenanthroline compound and process for preparing same | SONY CORP (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20050073641-A1 | Bathophenanthroline compound and process for preparing same | SHIBANUMA TETSUO (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| US-20040265626-A1 | Optical recording medium | JOLED INC. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | disclosed |
| US-5772990-A | Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated | L'OREAL (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5756092-A | DRUGS OR COSMETIC MIXTURE TREATING SKIN DISORDERS, ALOPECIA | SOCIETEL'OREAL S.A. (FR) | 1998-05-26 | — | — | US | disclosed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736300-A2 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | L'OREAL (FR) | 1996-10-09 | — | — | EP | disclosed |
| JP-H05186315-A | HAIR-THINNING SUPPRESSIVE COMPOSITION | L'OREAL SA | 1993-07-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050073641-A1 | Bathophenanthroline compound and process for preparing same | BZW1, BZW2, RPAP1 | DNM2 2650/4885NUDT1 967/4885MAPT 3832/4885 |
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | TYR, TH, MC1R | DNM2 3991/4885NUDT1 38/4885MAPT 3671/4885 |
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | DNM2 3584/4885NUDT1 4169/4885MAPT 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.